Skip to content
Fluvastatin
Lescol (fluvastatin) is a small molecule pharmaceutical. Fluvastatin was first approved as Lescol on 1993-12-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Lescol (generic drugs available since 2012-04-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluvastatin sodium
Tradename
Company
Number
Date
Products
LESCOL XLNovartisN-021192 RX2000-10-06
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fluvastatinANDA2023-02-23
lescolNew Drug Application2020-09-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coronary artery diseaseD003324I25.1
hypercholesterolemiaHP_0003124D006937
hyperlipoproteinemiasD006951
hypertriglyceridemiaEFO_0004211D015228
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C10: Lipid modifying agents
C10A: Lipid modifying agents, plain
C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
C10AA04: Fluvastatin
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_00031244318
DyslipidemiasD050171HP_0003119145
HypertensionD006973EFO_0000537I10134
Coronary diseaseD00332733
Kidney transplantationD0160301123
AtherosclerosisD050197EFO_0003914I25.1112
Myocardial infarctionD009203EFO_0000612I21112
Type 2 diabetes mellitusD003924EFO_0001360E11112
Drug interactionsD004347112
Metabolic syndromeD024821EFO_0000195E88.8122
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98112
ProteinuriaD011507HP_0000093R8011
Erectile dysfunctionD007172EFO_0004234F52.2111
Hyperlipoproteinemia type iiD006938EFO_0004911E78.0011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.2112
Hereditary nephritisD009394EFO_0004128Q87.8111
HepacivirusD01617411
InflammationD00724911
AgingD000375GO_0007568R41.8111
Chronic hepatitis cD019698EFO_0004220B18.211
Prostatic neoplasmsD011471C6111
Antiphospholipid syndromeD016736EFO_0002689D68.6111
Breast neoplasmsD001943EFO_0003869C5011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_000052011
Healthy volunteers/patients11
MelanomaD00854511
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFLUVASTATIN
INNfluvastatin
Description
(3R,5S)-fluvastatin is a (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which the stereocentres beta- and delta- to the carboxy group have R and S configuration, respectively. The drug fluvastatin is an equimolar mixture of this compound and its enantiomer. It is a (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid and a statin (synthetic). It is a conjugate acid of a (3R,5S)-fluvastatin(1-). It is an enantiomer of a (3S,5R)-fluvastatin.
Classification
Small molecule
Drug classenzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
Identifiers
PDB1HWI
CAS-ID93957-54-1
RxCUI41127
ChEMBL IDCHEMBL2220442
ChEBI ID38562
PubChem CID446155
DrugBankDB01095
UNII ID4L066368AS (ChemIDplus, GSRS)
Target
Agency Approved
HMGCR
HMGCR
Organism
Homo sapiens
Gene name
HMGCR
Gene synonyms
NCBI Gene ID
Protein name
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Protein synonyms
3-hydroxy-3-methylglutaryl CoA reductase (NADPH), HMG-CoA reductase, hydroxymethylglutaryl-CoA reductase
Uniprot ID
Mouse ortholog
Hmgcr (15357)
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Q5U4I2)
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000037346SLCO1B1, 521T>C, Val174Aladrug response2022-02-151A
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,841 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
38,270 adverse events reported
View more details